Relapsed or Refractory B-cell Malignancy(NHL/ALL)
1 clinical trials · Condition
◉ Watch Relapsed or Refractory B-cell Malignancy(NHL/ALL)
| Record | Firm | Date |
|---|---|---|
| A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL) (NCT04933825) | EdiGene (GuangZhou) Inc. | 2021-07-20 |
Track Relapsed or Refractory B-cell Malignancy(NHL/ALL) automatically
Every clearance here is in the API, with alerts when new ones post.